• Tuesday, March 3, 2020 @ 12:00 am

Addex Therapeutics Ltd (Nasdaq & SIX: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today the appointment of one of the world’s leading and most successful neuroscience drug research and developers, Darryle D. Schoepp PhD, as Chairman of its newly formed scientific advisory board (SAB). Dr. Schoepp has over thirty years experience in the field, including 20 years at Eli Lilly as a scientist and leader of the neuroscience research department, and 11 years at Merck as the neuroscience research therapeutic area leader. During his career, Dr. Schoepp has been involved in the discovery of over 20 novel first in class agents for psychiatric and neurological diseases.

“Darryle has been pioneering novel approaches in neuroscience drug discovery and development for over three decades. His contribution to the neurology field is second to none and we are honored to have him join our team to help steer Addex’s scientific strategy,” said Tim Dyer, CEO of Addex. “Building an SAB is a key next step for Addex as we advance our in-house discovery preclinical portfolio of drug candidates and maintain our leadership position in allosteric modulator drug discovery.”

“I have followed the progress Addex has made in the field of allosteric modulation since inception and have been impressed by the discoveries they have made", said Dr. Schoepp. “I am delighted to join the team and very much look forward to bring my experience to help Addex advance its exciting portfolio and discovery platform."

Dr. Schoepp has published over 200 peer reviewed papers and is an inventor of 15 U.S. patents. His research has resulted in major contributions to the role of excitatory amino acid neurotransmitter glutamate in disease pathophysiology, pharmacology and therapeutics. Dr. Schoepp has been involved in the discovery of the first AMPA/kainate and metabotropic receptor negative and positive modulators for migraine, pain, cognition, anxiety disorders and schizophrenia. While at Lilly, he was a co-discoverer of the compound alivimopan (Entereg), a first in class peripherally restricted opioid antagonist for post-operative ileus.

At Merck, Dr. Schoepp and his team built a pipeline of innovative first in class agents for Alzheimer’s disease, Parkinson’s disease, pain/migraine, and schizophrenia, including the first in class orexin receptor antagonist Suvorexant (Belsomra) for insomnia and the first in class oral CGRP antagonist ubrogepant (Ubrelvy) for migraine treatment. Dr. Schoepp earned his PhD in toxicology and pharmacology from the University of West Virginia.

You may also be interested in